期刊文献+

肥厚梗阻型心肌病经皮腔内室间隔支化学消融术靶血管及终点的研究 被引量:1

下载PDF
导出
摘要 目的 探讨肥厚梗阻型心肌病 (HOCM)经皮腔内室间隔支化学消融术 (PTSMA)靶血管的选择及消融终点的确定。方法 经皮穿刺股动脉 ,造影、测压、确定靶血管后 ,采用球囊封堵并注射无水酒精 ,当左心室流出道压力 (LVOTG)阶差降至正常时为消融终点。术后 2 4小时及每月行经胸超声心动图 (TTE)及心电图检查 ,门诊记录临床症状变化。结果  38例HOCM患者静息状态下LVOTG阶差 >30mmHg或激发试验时 >5 0mmHg ,7例肥厚部位同时累及左心室侧壁和右心室。靶血管选定第一间隔支 (S1) 35例、第二间隔支 (S2 ) 3例 ,平均注射酒精 2 8(0 4~ 9)ml;消融后即刻压力阶差均 <30mmHg ,且出现心脏传导阻滞 ,判断为消融终点。术前平均收缩期二尖瓣前向移动(SAM ) 3 7级 ,室间隔厚度 (IVST) 2 3 5mm ,LVOTG阶差 6 2 4mmHg ,左室射血分数 (LVEF) 5 7 5 % ,左室舒张末内径 (LVEDd) 34 2mm ;术后随访结束时上述值分别为 1 2级 ,19 8mm ,2 4 6mmHg ,6 3%及 4 2 1mm(P <0 0 5或P <0 0 1)。结论 S1是最主要的靶血管 ,出现固定性传导阻滞与LVOTG阶差正常是消融的终点 ;
出处 《江苏医药》 CAS CSCD 北大核心 2003年第10期757-758,共2页 Jiangsu Medical Journal
  • 相关文献

参考文献5

  • 1陈绍良,段宝祥,何晓红,张幼祥,叶飞,刘志忠,纪勤炯,毛鑫祥.梗阻性肥厚型心肌病经皮化学消蚀术后长期随访研究[J].中国介入心脏病学杂志,2003,11(1):21-24. 被引量:4
  • 2Seggewiss H,Gleichmann U,Faber L,et al.Percutaneous transluminal septal myocardial ablation(PTSMA)in hypertrophic obstructive cardiomyopath:Acute results and 3-month follow-up in 25 patients.J Am Coll Cardiol,1998,31:252-258.
  • 3Faber L,Seggewiss H,Gleichmann U.Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopath:acute and 3-month follow-up results with respect to myocardial contrast echocardiography.Circulation,1998,98:2415-2421.
  • 4Kuhn H,Gietzen F,Leuner C,et al.Induction of subaortic ischemia to reduce obstruction In obstructive cardiomyopath.Eur Heart J,1997,18:846-851.
  • 5Gietzen F,Leuner CH,Raute-Kreinsen U,et al.Acute and long-term results after trancoornary ablation of septum hypertrophy(TASH).Catheter interventional treatment for hypertrophic oobstructive cardiompopath.Eur Heart J,1999,20:1342-1354.

二级参考文献7

  • 1[1]Sigwart U. Non-surgical myocardial reduction of hypertrophic obstructive cardiomyopath. Lancet, 1995,346:211-214.
  • 2[2]Seggewiss H, Gleichmann U, Faber L, et al. percutaneous transluminal septal myocardial ablation (PTSMA) in hypertrophic obstructive cardiomyopath: Acute resulls and 3-month follow-up in 25patients. J Am Coll Cardiol, 1998,31:252-258.
  • 3[3]Faber L, Segg,ewiss H, Gleichmann U. Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopath:acute and 3-month follow-up results with respect to myocardial contrast echocardiography. Circulation, 1998,98:2415-2421.
  • 4[4]Kuhn H, Gietzen F, Leuner C, et al. Induction of subaortic ischemia to reduce obstruction In obstructive cardiomyopath. Eur Heart J, 1997,18:846-851.
  • 5[5]Gietzen F, Leuner CH, Raute-Kreinsen U, et al. Acute and long-term results after trancoomary ablation of septum hypertrophy (TASH).Catheter interventional treatment for hypertrophic oobstructive cardiomyopath. Fur Heart J, 1999,20:1342-1354.
  • 6[6]Naguhe SF, Lakiss NM, HeZ-X, et al. Role of myocardial contrast echocardiography during nonsurgical reduction therapy for hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol, 1998,32:225-229.
  • 7[7]Seggewiss H, Faber L, Gleichmann U. Percutaneous transluminal septal myocardial ablation for hypertrophic obstructive cardiomyopath.Thorac Cardiovasc Surg, 1999,47:94-100.

共引文献3

同被引文献5

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部